Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer.

Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric population, the company announced on Thursday. The trial aims to enroll around 12,000 participants aged 2 to 17,

Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., Sanofi has

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease prospect to its late-phase pipeline.

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly became a blockbuster medicine following its approval two years ago.

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet. Read why MRK is a Buy.